139 related articles for article (PubMed ID: 20350948)
1. Activity of drug combinations against dormant Mycobacterium tuberculosis.
Filippini P; Iona E; Piccaro G; Peyron P; Neyrolles O; Fattorini L
Antimicrob Agents Chemother; 2010 Jun; 54(6):2712-5. PubMed ID: 20350948
[TBL] [Abstract][Full Text] [Related]
2. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.
Piccaro G; Giannoni F; Filippini P; Mustazzolu A; Fattorini L
Antimicrob Agents Chemother; 2013 Mar; 57(3):1428-33. PubMed ID: 23295931
[TBL] [Abstract][Full Text] [Related]
3. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
4. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
5. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
[TBL] [Abstract][Full Text] [Related]
7. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
8. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
[TBL] [Abstract][Full Text] [Related]
9. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
10. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
Aguilar-Ayala DA; Cnockaert M; Vandamme P; Palomino JC; Martin A; Gonzalez-Y-Merchand J
J Med Microbiol; 2018 Mar; 67(3):282-285. PubMed ID: 29458544
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
13. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
16. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST
Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication.
Lee WY; Ling M; Anderson G; Achawal S; Thaker HK
J Med Microbiol; 2011 Oct; 60(Pt 10):1550-1552. PubMed ID: 21659503
[TBL] [Abstract][Full Text] [Related]
19. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
Gosling RD; Uiso LO; Sam NE; Bongard E; Kanduma EG; Nyindo M; Morris RW; Gillespie SH
Am J Respir Crit Care Med; 2003 Dec; 168(11):1342-5. PubMed ID: 12917230
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
